Skip to main content

Peer Review reports

From: Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis

Original Submission
18 Oct 2018 Submitted Original manuscript
12 Feb 2019 Author responded Author comments - Joshua David Wallach
2 Dec 2018 Reviewed Reviewer Report - Peter Lurie
24 Nov 2018 Reviewed Reviewer Report - Mamoru Narukawa
12 Jan 2019 Reviewed Reviewer Report - Barbara Mintzes
Resubmission - Version 2
12 Feb 2019 Submitted Manuscript version 2
10 Apr 2019 Author responded Author comments - Joshua David Wallach
3 Mar 2019 Reviewed Reviewer Report - Peter Lurie
1 Mar 2019 Reviewed Reviewer Report - Mamoru Narukawa
2 Apr 2019 Reviewed Reviewer Report - Barbara Mintzes
Resubmission - Version 3
10 Apr 2019 Submitted Manuscript version 3
3 May 2019 Author responded Author comments - Joshua David Wallach
24 Apr 2019 Reviewed Reviewer Report - Peter Lurie
Resubmission - Version 4
3 May 2019 Submitted Manuscript version 4
Publishing
8 May 2019 Editorially accepted
17 Jun 2019 Article published 10.1186/s12916-019-1344-3

You can find further information about peer review here.

Back to article page
\